Phaseline

Targets › ENV

ENV: drug programs, companies and trials

9 programs from 5 companies in 23 trials: 12 Phase 1, 7 Phase 2, 4 Phase 3; Infectious disease; next expected readout Nov 2026.

Open in Phaseline: the race on ENV, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Gilead SciencesTeropavimab
Anti-gp120 monoclonal antibody
ENVPhase 3HIV Infections; HIV-1-infection; HIV-1 InfectionMar 2029
Gilead SciencesZinlirvimab
Envelope protein inhibitor
ENVPhase 3HIV Infections; HIV-1-infection; HIV-1 Infection; HIV/AIDS and Infections …Mar 2029
National Institute of Allergy and Infectious Diseases (NIAID)VRC07-523LS
Broadly neutralizing antibody against HIV-1 envelope protein
ENVPhase 2HIV; Acute HIV Infection; HIV Infection; HIV-1Dec 2026
TaiMed BiologicsTMB-380
Broadly neutralizing antibody (bNAb) against HIV; monoclonal antibody that binds to HIV en
ENVPhase 2HIV -1 InfectionMay 2027
National Institute of Allergy and Infectious Diseases (NIAID)16055 NFL Delta Gly4 Env Protein Trimer
HIV envelope protein (gp120/gp41) trimer vaccine immunogen
ENVPhase 1HIVNov 2026
University of California, San Francisco[89]Zr-DFO-VRC01
Radiolabeled anti-HIV-1 envelope monoclonal antibody
ENVPhase 1HIV-1-infectionDec 2026
National Institute of Allergy and Infectious Diseases (NIAID)BG505 MD39.3 gp151 CD4KO mRNA
HIV gp151 envelope trimer mRNA vaccine with CD4 binding site knock-out
ENVPhase 1HIV InfectionsJun 2027
National Institute of Allergy and Infectious Diseases (NIAID)VRC01
Broadly neutralizing antibody against HIV-1 envelope glycoprotein gp120
ENVPhase 1HIV InfectionJan 2028
Steven DeeksLVgp120duoCAR-T cells
CAR-T cells expressing dual CAR targeting gp120, the envelope glycoprotein of HIV
GP120, ENVPhase 1HIV InfectionsDec 2028

Conditions

HIV (4) HIV Infection (4) HIV Infections (4) HIV-1-infection (4) HIV-1 (2) HIV-1 Infection (2) Acute HIV Infection (1) HIV/AIDS and Infections (1) HIV -1 Infection (1)

Modalities

mixed (4), protein or peptide (2), small molecule (2), other (1)

Companies

National Institute of Allergy and Infectious Diseases (NIAID) (4) Gilead Sciences (2) TaiMed Biologics (1) Steven Deeks (1) University of California, San Francisco (1)

Related targets

GP120 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.